Refine by
Implant Utilizing Ebr Systems Articles & Analysis: Older
69 news found
Anuncia Medical Inc. (“Anuncia” or the “Company”), a Company specializing in advancing innovations for implantable and external cerebrospinal fluid (CSF) management systems, is pleased to announce the successful first implant of the Company’s FDA-cleared ReFlow™ Mini Flusher device in tandem with a “sonolucent” cranial plate (Clearfit® Cover, ...
In the ever-evolving field of pharmaceuticals, CD Formulation has emerged as a major player in developing innovative drug delivery systems aimed at enhancing the efficacy and safety of therapies. Through its expertise in various cutting-edge technologies such as microneedle and thin film technologies, transdermal patches, microencapsulation, and nanoparticle development, CD Formulation is ...
Intermountain Primary Children’s Hospital First in the Country to Implant this Next Generation FDA-Cleared Device Company Welcomes Vice President of Sales & Marketing, Mark Geiger, Who Lives with Hydrocephalus Anuncia Medical Inc. (“Anuncia” or the “Company”), a Company specializing in advancing innovations for implantable and external cerebrospinal fluid ...
CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, has launched a new line of Locust Bean Gum with advanced technical platforms to help scientists advance biopharmaceutical research. Over the past few decades, researchers have been working on developing delivery systems that can reduce side effects while improving efficacy. Natural polymers are ...
Flowonix Medical Inc. of New Jersey, and Colorado-based Cerebral Therapeutics, announced today the first patients implanted with the Prometra II Programmable Infusion System in the Australian Direct Drug Administration for Refractory Epilepsy (ADDRESS) clinical trial at St. Vincent's Hospital, Melbourne, Australia. The jointly developed therapy features a micro-infusion device that tightly ...
MINNEAPOLIS, July 12, 2022 - CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), developer of the world's first FDA-approved neuromodulation device to treat the symptoms of heart failure, has launched its new Barostim Programmer, which was approved by the U.S. Food and Drug Administration (FDA) earlier this year. The second-generation programmer has a modernized design, operates on an upgraded cellular network ...
ByCVRx
Procyrion, Inc., a medical device company developing a catheter-deployed micropump for the management of chronic heart failure, has named Eric S. Fain, MD as President and Chief Executive Officer effective immediately. The Board of Directors tapped Dr. Fain to build upon the foundation of innovative technology established over recent years and accelerate the progression of product development ...
EMPOWR Acetabular™ is DJO’s modern, premium, intelligently designed acetabular system featuring advanced fixation technologies, efficient instrumentation, and a feature enabling future dual mobility offering.1 This system – combined with our femoral stem options which all have 12/14 robust micro-threaded trunnions – provides surgeons a comprehensive THA solution for all ...
Neuspera Medical, a medical device company developing implantable devices for patients battling chronic illnesses, today announced it will begin enrollment in its pivotal clinical trial (SANS-UUI), a single-arm study that will enroll 145 patients at 25 sites globally. The study will evaluate the safety and efficacy of Neuspera’s Nuvella™ system designed to treat overactive bladder ...
Bluegrass Vascular Technologies, a private medical technology company focused on innovating lifesaving devices and methods for vascular access procedures, announced today the publication of a paper reporting on the use of the Surfacer® System to perform the Inside-Out® procedure via transcollateral approach. “The Surfacer Inside-out system represents a new approach to restore ...
GRAND RAPIDS, Mich., March 14, 2022—Shoulder Innovations LLC., (SI), a leading innovator in the development of shoulder replacement systems, announces the FDA Clearance of their latest component of the InSetTM Total Shoulder System, the InSetTM Stemless Humeral System. The InSetTM Stemless implant is the latest addition to the innovative and integrated InSetTM system, which already includes ...
Surgical Planning Associates, Inc. announces a new HipXpert software release that now includes the addition of DePuy Synthes’ PINNACLE® Acetabular Cup System and the ACTIS®, CORAIL®, SUMMIT®, and TRI-LOCK® Hip Systems to our patient-specific surgery planning and navigation system. HipXpert’s open-platform, 3D surgery planning software now supports more than 20 ...
ByHipXpert
Nalu Medical (“NALU”) announces the “Haleakala” update, substantially upgrading both the software and firmware of their award-winning Nalu Neurostimulation System. This update adds significant new capabilities for both spinal cord stimulation (SCS) and peripheral nerve stimulation (PNS). The update broadens the stimulation pulse width parameter to the widest range ...
Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced the launch of its “Don’t Wait for Too Late” educational campaign designed to raise awareness among the optometric community of minimally invasive glaucoma surgery (MIGS) as an ...
Ascensia Diabetes Care, a global diabetes company, announces that its partner Senseonics has received approval from the U.S. Food and Drug Administration (FDA) of the next-generation Eversense® E3 continuous glucose monitoring (CGM) System. Ascensia plans to make the E3 sensor, which can be used for up to six months, available to patients in the U.S. during the second quarter of 2022. Robert ...
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the approval of the next-generation Eversense® E3 CGM System by the Food and Drug Administration (FDA). The Eversense E3, including proprietary sacrificial ...
Today, the Johnson & Johnson Medical Devices Companies* announced that DePuy Synthes** has acquired CrossRoads® Extremity Systems, a Tennessee-based foot and ankle company that provides a broad range of procedure-specific, sterile-packed implants and instrumentation systems cleared for lower extremity indications. Private equity firm HealthpointCapital was the majority investor and worked ...
Hyalex welcomes executive team member, Chris Cain, serving as Vice President of Clinical and Regulatory Affairs. Chris joins the Hyalex team with an impressive background in leading numerous clinical trials of implanted medical devices and taking innovative technologies through US PMA and international regulatory approvals. Chris provides the experience necessary to bring the HYALEX® ...
Hyalex Orthopaedics, a privately-held medical device company developing transformational cartilage biomimetic products, today announced the appointment of Carl Vause as its new chief executive officer and president. Mr. Vause, who succeeds Hyalex’s interim president, Michael Hawkins, Ph.D., has also been appointed to the company’s board of directors. Additionally, Dr. Hawkins has ...
Confluent Medical Technologies (“Confluent”), a leading materials science, development and manufacturing partner to medical device manufacturers (“OEMs”), today announced that TPG Capital, the private equity platform of alternative asset management firm TPG, has agreed to make a majority investment in the company. TPG Capital joins existing investor Ampersand Capital ...